Evidence map›Paper›PMID 38430428›Full record

ArticleAnnals of surgical oncology2024

Initial Experience Using Laparoscopic HIPEC for Gastric Cancer with Peritoneal Metastasis: Safety and Outcomes.

Meagan D Read, Justin Drake, Ghazal Hashemipour, Benjamin D Powers, Rutika Mehta, Andrew Sinnamon, Jose M Pimiento, Sean P Dineen

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meagan D Read *Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Justin Drake *Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Ghazal HashemipourDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Benjamin D PowersDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Rutika MehtaDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Andrew SinnamonDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jose M PimientoDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Sean P DineenDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. sean.dineen@moffitt.org.ORCID http://orcid.org/0000-0002-2012-2238

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeritoneal metastases (PM) develop in approximately 20% of patients with gastric cancer (GC). For selected patients, treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promising results. This report aims to describe the safety and perioperative outcomes of laparoscopic HIPEC for GC/PM.

methodsThis retrospective cohort study evaluated patients who had GC and PM treated with laparoscopic HIPEC (2018-2022). The HIPEC involved cisplatin and mitomycin C (MMC) or MMC alone. The primary end point was perioperative safety.

resultsThe 22 patients in this study underwent 27 procedures. The mean age was 58 ± 13 years. All the patients were Eastern Cooperative Oncology Group (ECOG) 0 or 1 (55 and 45%, respectively). Five patients underwent a second laparoscopic HIPEC, with a median of 126 days (interquartile range [IQR], 117-166 days) between procedures. The median peritoneal carcinomatosis index (PCI) was 4 (IQR, 2-9), and the median hospital stay was 2 days (IQR, 1-3 days). No 30-day readmissions or complications occurred. Eight patients (36%) underwent gastrectomy (CRS ± HIPEC). After an average follow-up period of 11 months, 7 (32%) of the 22 patients were alive. The median overall survival was 11 months (IQR, 195-739 days) from the initial procedure and 19.3 months (IQR, 431-1204 days) from the diagnosis.

conclusionsLaparoscopic HIPEC appears to be safe with minimal perioperative complications. Approximately one third of the patients undergoing initial laparoscopic HIPEC ultimately proceeded to cytoreduction and gastrectomy. Preliminary survival data from this highly selected cohort suggest that the addition of laparoscopic HIPEC to systemic chemotherapy does not compromise other treatment options. These initial results suggest that laparoscopic HIPEC may offer benefit to patients with GC and PM and aid in the selection of patients who may benefit from curative-intent resection.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyLaparoscopyMitomycinPeritoneal NeoplasmsStomach NeoplasmsAgedChemotherapy, Cancer, Regional PerfusionCisplatinCombined Modality TherapyFemaleFollow-Up StudiesGastrectomyHumansMaleCisplatinMitomycin

Identifiers

PMID38430428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.